The apheresis equipment market size is estimated to be USD 2,825.12 million in 2022 and is expected to witness a CAGR of 11.12% during the forecast period 2023-2033. Rising demand for blood component and increasing blood disorders are factors contributing to the market growth. Additionally, availability of supportive government initiatives, reimbursement structure, surge in popularity and involvement in blood donation are other factors supporting the market growth. However, high price of the apheresis procedure and associated equipment, together with the significant capital investment required is expected to hinder the growth.

Rising demand for blood components is expected to propel the market growth during the projected period. Red blood cells are used to treat anemia, which occurs when your blood lacks enough healthy red blood cells to supply oxygen to body tissues. According to the American Red Cross, approximately 29,000 units of red blood cells are required every day in the United States. Patients with chronic diseases such as liver disease and myelofibrosis require platelet transfusions.

Increasing blood disorders is predicted to fuel the market growth during the forecast period. Blood disorders are diseases that make it difficult for the blood to operate normally. Red blood cells, white blood cells, and platelets are the three main blood cell types that are most commonly affected by blood diseases. Some of the prevalent blood disorders include anemia, bleeding issues such as hemophilia, and blood cancers including leukemia, lymphoma, and myeloma. Leukemia, a disease of the body’s blood-forming tissues was estimated by the American Cancer Society to have caused 61,090 new cases and 23,660 deaths in the United States in 2021. Patients with leukemia get blood transfusions to replace their red and platelet cells with healthy donor cells. The bone marrow, where blood is produced, is where the majority of blood malignancies start.

Segmentation

By Product

The market is categorized into device, disposable apheresis kits. In the global market, the disposable apheresis kits segment accounted for the largest revenue share in 2022 owing to the significant advancements in the production of blood bags, disposable kits, and tubing. The segment is expanding as a result of rising demand for automated component separation processes, particularly in developed markets. Patients with thrombocytopenia and significantly impaired platelet function often use the disposable kits. Therefore, it is anticipated that the segment expansion will be fueled by the availability of high-quality kits for the best patient treatment. Additionally, due to disposable apheresis kits’ rising popularity and low cost, small producers have access to a wide range of services. Filters, separators, tubing sets, and other components are put together as kits. The device segment is expected to grow at a high rate during the projected period. The increase in demand for automated blood component separators, improved healthcare infrastructure, and an increase in blood donation activities are some of the factors contributing to the growth. The launch of advanced, automated apheresis machines and rising demand in developing nations are anticipated to propel the segment’s expansion.

By Application

The market is segregated into neurology, haematology, renal diseases, and others. In the global market, the neurology segment accounted for the largest revenue share in 2022 owing to inevitable requirement for therapeutic apheresis in the management of very prevalent neurological disorders including multiple sclerosis and autoimmune neurological condition. According to the Atlas of MS, 2.8 million people globally (or 35.9% of the population) have multiple sclerosis. The average age at diagnosis is 32 years, and there are 2.1 new cases of the disease for every 100,000 persons worldwide in the 75 reporting countries. More than twice as many women as men suffer from multiple sclerosis. Additionally, it is anticipated that increasing R&D and supportive government activities for neurological disorders will accelerate segmental expansion. The hematology segment is anticipated to experience significant expansion throughout the projection period. The high growth of the market can be related to the increase in blood diseases. The American National Red Cross estimates that between 90,000 and 100,000 Americans have sickle cell disease. Additionally, the disease affects approximately 1,000 newborns each year.

By Technology

The market is divided into centrifugation and membrane filtration. In 2022, the centrifugation segment accounted for the largest revenue share owing to its increasing usage rates, centrifugation produces results that are simpler, faster, and more accurate than membrane filtering. To increase product efficiency, companies are creating technologically advanced and automated systems. The manufacturers are creating automated apheresis equipment with continuous flow centrifugation, an automated interface system, and a customized anticoagulant infusion system. The process of separating the blood is now quicker and more effective thanks to the use of automated equipment. For instance, NexSys PCS, an automated system that enhances efficiency while simultaneously enhancing quality and compliance in plasma collection centres was developed by Haemonetics Corp. Compared to centrifuges, which are useful for specialised cell separation, membrane filters are substantially more useful for separating plasma from other cellular components. This procedure takes less time, prevents the loss of blood coagulation factors, and reduces the requirement for replacement fluids. This technology’s high adoption in developed Western European regions and Japan can be attributed to its higher efficacy.

Regional Markets

In 2022, North America region accounted for the highest revenue in the apheresis equipment market and is expected to maintain its dominance during the forecast period. This is attributed to the increasing incidence of blood-related diseases such as kidney disease, metabolic disease, cancer, and neurological disorders, surge in number of donors, and the demand for blood components. The American National Red Cross estimates that about 6.8 million Americans donate blood annually. Furthermore, someone needs blood or platelets every two seconds. Thus, the industry in the United States is being driven by an increase in blood transfusions and donation camps. On the other hand, the Asia Pacific market is anticipated to exhibit the fastest CAGR. One of the main reasons for this increase in revenue share is the rising prevalence of blood diseases that require platelet and plasma transfusions in developing nations such as India and China. Additionally, during the projection period, the industry is anticipated to benefit from an enhanced growth environment due to the region’s expanding healthcare practitioner population and improved healthcare infrastructure.

Competitor Insights

Some of the key players operating in the apheresis equipment market are Fresenius Kabi AG, Mallinckrodt, Hemacare, Terumo BCT, Inc., Nikkiso Europe GmbH, Therakos, Haemonetics Corporation, Fenwal, B. Braun Melsungen AG, Asahi Kasei Medical Co., Ltd., and Cerus Corporation.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Terumo Blood and Cell Technologies increased its capacity for production in October 2021 by building a new $60 million USD manufacturing facility in Costa Rica. In addition to manufacturing other products, the Costa Rica facility will support Spectra Optia Apheresis System’s 130-country global supply chain.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, procedure, application, and end use from 2023 to 2033.

Report Scope:

Segmentation: Apheresis Equipment Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Device
• Disposable Apheresis Kits

Procedure (Revenue, USD Million), 2022 – 2033

• LDL Apheresis
• Plasmapheresis
• Leukapheresis
• Plateletpheresis
• Erythrocytapheresis
• Photopheresis
• Others

Application (Revenue, USD Million), 2022 – 2033

• Neurology
• Haematology
• Renal Diseases
• Others

End Use (Revenue, USD Million), 2022 – 2033

• Centrifugation
• Membrane Filtration

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA